Lupin Q1 FY24 Growth Metrics and ESG Goals
Vision
A pharmaceutical company focused on delivering high quality medicines to patients around the world
LUPIN
United
States
Evolving portfolio and
pipeline in Complex
platforms (Inhalation,
Biosimilars and
Injectables)
Scaled product
platforms in legacy oral,
ophthalmic and
dermatology
Global
Developed
Markets
India Region
Global operational
efficiency and
presence driving
leverage on CAPEX and
R&D across the
platforms through
markets with similar
regulatory regimes
(UK, Europe, Canada
and Australia)
Delivering innovative
brands at above
market Growth
through organic and in-
organic means, as well
as establishing strategic
market adjacencies
Other
Emerging
Markets
Global reach and scale
positions us as a partner
of choice in South Africa,
Brazil, Mexico,
Philippines
Enhancing Access to
Medicines in anti-TB in
low and middle income
nations
Continuous Improvement Culture
Best in Class Global Quality
ΑΡΙ
Meaningful scale
achieving competitive
costs to serve internal
as well as external
customers and
contribute
meaningfully to Global
Public Health
13View entire presentation